Gunmen kill 1, wound 13 at Sri Lanka election campaign (AP)
IDF soldier wounded in air force base fire last month succumbs to wounds (Haaretz)
- 11:50 AM
Turkey: 5 killed in clashes between authorities and PKK (Reuters)
- 11:27 AM
- 11:18 AM
- 11:08 AM
Fear of rioting, disorder at Temple Mount prompt restrictions on Muslim worshiper (Haaretz)
- 8:48 AM
- 6:49 AM
Mexico: Death toll 27 after truck hits religious procession (AP)
Mexico approves U.S. extradition warrant for fugitive kingpin 'El Chapo' (Reuters)
Surfer seriously injured in Australian shark attack (AP)
Greece's Tsipras asserts control over party with congress vote (Reuters)
- 12:46 AM
Teva gets FDA nod for generic prostate cancer pain drug
Can begin shipping Mitoxantrone Hydrochloride injection USP immediately
Teva Pharmaceutical Industries said on Wednesday the Food and Drug Administration has granted final approval for the company's generic treatment for patients with prostate cancer, and it will begin shipping the product immediately.
The drug, called Mitoxantrone Hydrochloride injection USP, is used in combination with corticosteroids as initial treatment for patients in pain from advanced hormone-refractory prostate cancer.
It can also be used in combination with other products for the initial therapy for acute nonlymphocytic leukemia in adults.
The Teva drug is the equivalent of Novantrone injection from Swiss biotech Serono.